Retatrutide is a synthetic peptide developed as a triple agonist targeting the GLP-1, GIP, and glucagon receptors simultaneously. It is studied in metabolic and endocrinology research for its combined receptor-agonist activity across these three pathways. Supplied as a 10mg lyophilized powder per vial, sealed for laboratory stability. Store frozen, protected from light and moisture, and reconstitute only immediately prior to research use.